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Abstract: Malignant diseases present a serious public health burden and their treatment with
traditional chemotherapy cannot be considered an all-round solution, due to toxic side effects.
Selenium compounds (Se-compounds) have received substantial attention in medicinal chemistry,
especially in experimental chemotherapy, both as cytotoxic agents and adjuvants in chemotherapy.
A checkerboard microplate method was applied to study the drug interactions of Se-compounds
and clinically relevant chemotherapeutic drugs against the multidrug-resistant (MDR) subtype of
mouse T-lymphoma cells overexpressing the ABCB1 transporter. Se-compounds showed synergistic
interactions with chemotherapeutic agents targeting the topoisomerase enzymes or the microtubule
apparatus. The ketone-containing selenoesters showed synergism at lower concentrations (1.25 µM).
Most of the tested compounds interacted antagonistically with alkylating agents and verapamil.
A thiophene-containing Se-compound showed synergism with all tested drugs, except cisplatin.
While the exact mechanism of drug interactions is yet unknown, the potency of the selenocompounds
as efflux pump inhibitors or the potentiation of their efficacy as reactive oxygen species modulators
may play a role in their complementary activity against the tested MDR lymphoma cell line.
Keywords: anticancer; combination; checkerboard; selenium; lymphoma; doxorubicin; topotecan
1. Introduction
Malignant diseases are a significant public health burden, accountable for one-sixth of deaths
globally and have an estimated total economic cost of 1 trillion United States (US) dollars [1].
Lymphomas are blood cancers, originating from the body’s own immune cells (lymphocytes),
affecting around 111,000 people (Hodgkin-lymphomas: ~18,000; non-Hodgkin-lymphomas: ~93,000)
in the European Union (EU) alone (2012) [2]. High grade/rapidly growing lymphomas (frequently
affecting children) are very often difficult to treat [3–7]. Traditional (cytotoxic) chemotherapy is
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still the first-line treatment for an overwhelming majority of tumors, together with radiation
and surgical intervention [8–10]. Nevertheless, chemotherapy is coupled with serious, clinically
significant side effects, some that are foreseeable and characteristic for all such agents (due to their
effect on rapidly dividing normal cells in the body), while others are specific to some drugs (e.g.,
cardiomyopathy related to doxorubicin, hemorrhagic cystitis related to acrolein, a toxic metabolite
of cyclophosphamide), frequently leading to treatment discontinuation and decreased quality of
life (QoL) for the patients [11–15]. The importance and success of combination chemotherapy in
the treatment of malignant diseases has been described in detail both in the laboratory setting as
well as in clinical practice [16,17]. There are numerous studies demonstrating that using multiple
chemotherapeutic drugs, having synergistic interactions increases patient survival rate. In addition,
this therapeutic strategy allows for the dose reduction of individual drugs [18]. The relevance of
combination chemotherapy is further highlighted by the growing clinical problem of cancer multidrug
resistance (MDR) and tumor cell heterogeneity, often leading to treatment failure, especially when these
drugs are used as monotherapy [13,19–23]. Organoselenium compounds have received substantial
attention in medicinal chemistry, due to their pronounced biological and redox-modulating activities,
to such a great degree that “bio-selenium research” is being conducted related to cardiovascular,
autoimmune, endocrine, neurodegenerative and psychological conditions, from in vitro experiments
all the way to clinical trials [24–28]. There are a plethora of studies demonstrating the efficacy of
structurally dissimilar selenocompounds as novel anticancer agents, suggesting the significant role
of the selenium atom in these molecules [27,29–32]. The potential of redox-modulating compounds
in the management of therapy-refractory lymphomas has also been described [33,34]. In addition,
synergistic interactions have been observed between selenium (both in its elemental forms and as
various compounds) and a diverse range of chemotherapeutic drugs (cisplatin, irinotecan, imatinib,
paclitaxel) on colorectal, breast, lung, and leukemia cell lines, respectively [35–40].
In our previous studies, the design, synthesis and preliminary biological screening of a cyclic
selenoanhydride (1) and ten selenoesters (2–11, Figure 1) were performed [41]. The most active
compounds presented very promising anticancer properties on a variety of cell lines (with IC50 values
in the nanomolar range) and proved to be effective modulators of programmed cell death and of the
ABCB1 (ATP-binding cassette subfamily B member 1 or P-glycoprotein) multidrug efflux pump on both
murine and human model systems [42–44], in addition to having promising absorption, distribution,
metabolism, and excretion (ADME) properties based on in silico methods [45]. Based on our previous
results, the aim of the current study was to evaluate the potential pharmacological interactions between
clinically relevant anticancer drugs in vitro and these compounds with pronounced anticancer activity
against lymphoma and to explore the potential applications of these derivatives as co-adjuvants of
drugs currently used in cancer chemotherapy.
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2. Results and Discussion
In the present study, we have evaluated the abovementioned 11 selenocompounds (Se-
compounds), including the selenoanhydride 1 and the selenoesters 2–11 (Figure 1). Besides, we have
also included the phthalic anhydride (12) in our experiments to ascertain the crucial role of the
selenium atom in the activity of the phthalic selenoanhydride 1 (12 is its oxygen isostere), as well
as 3 chalcogen XCN salts (compounds 13–15, X=O, S, Se) to compare the activity of the organic
selenocompounds 1–11 with selected inorganic related salts. This study had a dual purpose: firstly,
to determine the efficacy of selenocompounds 1–11 as adjuvants in combinational chemotherapy
in an in vitro resistant lymphoma model (comparing it with the activity of the compounds 12–15);
additionally, to shed a light on the mechanism of action of the tested compounds, because their
interactions with the chemotherapeutic agents should be related to their own mechanism of activity.
Seven anticancer drugs (Table S1, in Supplementary Material) were tested with different mechanisms
of action, to establish the interactions of the respective drugs (one for each mechanism of action)
with the different selenocompounds. Briefly, we have evaluated the Se-compounds in combination
with two topoisomerase inhibitors (topotecan [Top] and doxorubicin [Dox]), a microtubule formation
inhibitor (vincristine [Vin]), two alkylating agents (cisplatin [Cis] and cyclophosphamide [Cpm]),
and two antimetabolites (methotrexate [Met] and 5-fluorouracil [5-FU]). Besides, we have tested an
efflux pump inhibitor (verapamil [Ver], which is not an anticancer drug) to evaluate the interaction of
the Se-compounds with this alternative mechanism of action. The concentrations at which anticancer
drugs and Se-compounds were tested are given in Tables S1 and S2 in the Supplementary Material.
The checkerboard combination assay is a widely used and convenient in vitro method for the
assessment of drug interactions among various pharmacological agents, especially when the data
obtained are analyzed using CompuSyn software. This program, besides enabling the calculation of
the combination indices, also allows the determination of the most effective ratios of combinational
agents, which could be relevant for possible subsequent clinical testing [46–48]. These combination
indexes are used to determine the type of interaction, according to Table 1.
Table 1. Summary of interaction types related to combination index (CI) values [48].
Combination Index (CI) Type of Interaction Combination Index (CI) Type of Interaction
0–0.1 very strong synergism 0.9–1.1 additive effect
0.1–0.3 strong synergism 1.1–1.2 slight antagonism
0.3–0.7 synergism
1.2–1.45 moderate antagonism
1.45–3.3 antagonism
0.7–0.85 moderate synergism 3.3–10 strong antagonism
0.85–0.9 slight synergism >10 very strong antagonism
The detailed ratios and the concentrations of the most effective combinations are given in the
Supplementary Material, in Tables S3–S10. These data are summarized in Figures 2–6, which group
the selenocompounds and the additional compounds/salts in relation to their chemical structure to
ease the interpretation of their interactions with the panel of anticancer drugs.
Figure 2 includes the phthalic selenoanhydride 1 and its oxygen isostere the phthalic anhydride
(12). This Se-compound interacts synergistically with doxorubicin and with vincristine, being the
optimal interaction at low concentrations of 1 (12.5 and 5 µM, respectively). These results suggest
that 1 may interact with the microtubules for its synergy with Vin. Regarding Dox, its effect could be
mediated by the generation of reactive oxygen species (ROS), as the selenocompounds can act either
as antioxidants or as prooxidants. This additional mechanism of action of Dox seems more probable
than the inhibition of the topoisomerase II enzyme, as the interaction of 1 with Top (a topoisomerase-I
inhibitor) is slightly antagonistic. On the other hand, the phthalic anhydride 12 generally interacts
with the different drugs (except for Met and Cis) at higher concentrations than its selenium isostere (1).
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Compound 12 only showed synergistic interactions with topotecan, vincristine and 5-FU, but at high
concentrations of 12 (25, 50 and 100 µM, respectively); its unique interaction at low concentration was
with methotrexate (12.5 µM) and was moderately antagonistic. Interestingly, compound 12 showed
additive effect with Dox, which supports the hypothesis of the ability of 1 to generate ROS thanks to
the antioxidant/pro-oxidant properties of the selenium atom. On the other hand, verapamil and the
selenoanhydride 1 interacted in an antagonistic manner, which is surprising taking into account that 1
was reported to be an efflux pump inhibitor (EPI) [42–44]. This may indicate a possible competition in
the binding of the two EPIs (1 and Ver) to the ABCB1 protein.
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Figure 2. Interactions of the phthalic selenoanhydride (1) and the phthalic anhydride (12) with
a panel of anticancer drugs (topotecan [Top], doxorubicin [Dox]), vincristine [Vin]), cisplatin [Cis],
cyclophosphamide [Cpm]), methotrexate [Met] and 5-fluorouracil [5-FU]) or an efflux pump inhibitor
(Verapamil [Ver]). Concentration of the tested compound is given according the legend; concentration
of the anticancer drug is given in numbers inside the graph (in bold: below 0.1 µM, in italics between
0.1 µM and 1 µM, and in grey above 10 µM).
Symmetric bi-functionalized dimethyl selenodiesters 2–5 showed (with certain exceptions)
synergistic or moderately synergistic interactions with verapamil and with most of the anticancer
drugs evaluated, except for cisplatin, as sho i Fig re 3. The drugs that showed more synergistic
interac ion (a d at lower concentrations of t - pounds) w re Vin and Cpm; whereas Cis
interac d in an a t gonist c man er and 5-F lted in be the less synergistic of the remaining
drugs, as it requires higher concentrations of the seleniu derivatives. Compounds 2 and 4 showed a
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strong synergistic interaction with Vin, and at relatively low concentrations of the Se-compounds (12.5
and 6.25 µM, respectively), which can suggest that these Se-compounds can affect microtubule stability.
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Figure 3. Interactions of the symmetric diselenodiesters (2–5) with a panel of anticancer drugs (Top, Dox,
Vin, Cis, Cpm, Met and 5-FU) or an efflux pump inhibitor (Ver). Concentration of the tested compound
is given according the legend; concentration of the anticancer drug is given in numbers inside the
graph (in bold: below 0.1 µM, in italics between 0.1 µM and 1 µM, and in grey above 10 µM).
It is noteworthy to highlight the contrast between the antagonistic interaction of 2–5 with Cis and
the synergistic interaction of 2–5 with Cpm, indicating that the direct alkylation is more positive than
the alkylating-like one of Cis. The symmetric thiophene derivative (2) may be the most adequate of the
Se-compounds because it did not present with any antagonistic interactions and secondly it interacts in
different synergistic degrees with Top, Vin, Cpm, and Met at a concentration of 12.5 µM. The dimethyl
pyridine-1,6-dicarboselenoate 3 had a differential effect on the anticancer drugs: at concentrations
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in the range 6.25–12.5 µM, it showed differential antagonistic interactions with Top, Cis and 5-FU,
whereas it interacted in different degrees of synergism with Dox, Vin, and Cpm. Finally, between the
benzene dicarboselenoates 4 and 5, the meta-substituted (4) showed interactions at equal or lower
concentration than the para-substituted (5), except in the case of Top. This suggests a possible influence
of the substitution in their capacity to interact with anticancer drugs.
The results of the combination assay with anticancer drugs for the selenoesters containing amides
(6) or oxygen esters (7,8) in their lateral chain indicated that none of these compounds exerted
synergistic interactions with the anticancer drugs at concentrations of the Se-compound below 20 µM,
thus limiting their potential application as chemotherapy adjuvants (Figure 4).
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Figure 4. Interactions of the carbamoyl selenoester (6) and of the R-ylcarbonyl selenoesters (7 and 8)
with a panel of anticancer drugs (Top, Dox, Vin, Cis, Cpm, Met and 5-FU) or an efflux pump inhibitor
(Ver). Concentration of the tested compound is given according the legend; concentration of the
anticancer drug is given in numbers inside the graph (in bold: below 0.1 µM, in italics between 0.1 µM
and 1 µM, and in grey above 10 µM).
The derivatives containing an oxygen ester (7 and 8) showed different grades of synergism with
vincristine at a concentration of 25 µM, and 7 also showed moderate synergism with cyclophosphamide
at this low concentration of Se-compound. The amide-containing derivative 6 only showed at this
concentration (25 µM of Se-compound) a slight synergism with Dox.
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Nevertheless, out of the 15 compounds evaluated the ketone-containing Se-compounds 9–11
(Figure 5) interacted with the different anticancer drugs at the lowest concentrations: all of them
showed interactions at Se-compounds concentrations in the range from 1.25 to 2.5 µM with the seven
selected anticancer drugs. In the case of the verapamil, antagonistic interactions were observed at a
higher concentration range for the Se-compounds (5–12.5 µM).
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The methyl-ketone derivative 9 exerted synergistic interactions with topotecan and vincristine at a
concentration of Se-compound as low as 1.25 µM, as well as moderately synergistic enhancements of the
activity of doxorubicin and cyclophosphamide at a concentration of 2.50 µM. In contrast, Se-compound
9 interacted in different grades of antagonism at concentration of 1.25 µM with Cis, Met, 5-FU,
and Ver. This differential behavior suggests that this ketone Se-compound may affect the topoisomerase
enzymes (as both Top and Dox are topoisomerase inhibitors), inhibit the microtubule formation and
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mediate the direct alkylation of DNA (Cpm). Alternatively, this compound hinders the remaining
mechanisms tested: the alkylation-like action of Cis, and the antimetabolite activity of Met and 5-FU in
the synthesis of folic acid and nucleotides, respectively. The antagonistic interaction between Ver and 9
is surprising, taking into account that this compound inhibited the ABCB1 efflux pump with a potency
up to 4-fold of the inhibitory activity determined for Ver in previous studies [42–44]. This observation
may suggest competition between the two ABCB1 inhibitors at the time of interacting with this
transmembrane efflux pump.
The two evaluated tert-butyl ketone selenoesters (10 and 11) showed a similar pattern of
interaction with the anticancer drugs and with Ver as the methyl-ketone 9 described above, with some
differences. Compound 10 interacted in different grades of synergism with Top and with Vin at a
concentration of Se-compound of 1.25 µM, and with Dox at 2.5 µM. Compound 10 showed additive
effect with Cis, and different grades of antagonism with Cpm, Met, 5-FU, and Ver. On the other hand,
compound 11 at a 2.5 µM concentration showed synergistic interactions with Top and Vin, additive
effect with Dox and different grades of antagonism with the remaining drugs. The result of the
interaction with verapamil is again surprising, as these two derivatives (10 and 11) were also potent
inhibitors of the ABCB1 efflux pump in the previous experiments. Summing up, based on the results
obtained, the tert-butyl ketone selenoesters have a more favorable interaction with the topoisomerase
inhibitors Top and Dox and with the microtubule inhibitor Vin.
The graphs representing the interactions between the inorganic XCN (X=O, S and Se for 13, 14 and
15, respectively) salts are provided in Figure 6. Overall, the oxygen salt and the sulfur salt seemed to
have better interaction profile against the different drugs than the potassium selenocyanate (15), as the
latter only improved the interaction of its oxygen/sulfur analogues in its interaction with Vin and with
Cis, but in both cases at high concentration of the salts (50 µM). Only KOCN (13) and NH4SCN (14)
were able to interact in a synergistic manner with an anticancer drug (Met) at a relevant concentration
in the biological assays (12.5 µM). Besides that, 13 showed synergistic interaction with Dox and 14 with
5-FU at a concentration of salt of 25 µM. On the other hand, the sulfur salt (14) showed an antagonistic
effect with Dox, and the selenium salt a moderately antagonistic interaction with methotrexate at this
25 µM concentration of the respective salt. These data suggest that the oxygen and the sulfur salt could
be potential antimetabolites in the synthesis of folic acid.
Summing up from the perspective of the anticancer drugs used, different grades of synergistic
interactions were mostly observed in the case of Vin (all selenocompounds, apart from derivative 6),
Dox (7 Se-compounds, all except 4, 7, 8 and 11), while six compounds showed different grades
of synergistic interactions with cyclophosphamide (2, 3, 5 and 7–9) and with methotrexate (2–6
and 8); and five with Top (2, 4 and 9–11) and 5-FU (2 and 4–7), respectively. These compounds
exhibited their beneficial effects in the concentration range between 1.25–100 µM. In contrast, mostly
antagonistic interactions were observed in the case of Cis (7 Se-compounds: 1, 3, 4, 7–9 and 11) and
Ver (7 Se-compounds: 1, 5, 6 and 8–11). As mentioned before, it is surprising that compounds with
a known ability to inhibit efflux pumps showed different grades of antagonistic interactions with
a known EPI as Ver. This could be explained considering that the two EPIs (Ver and the respective
selenocompound) may have a competitive binding to the ABCB1 protein when ABCB1-overexpressing
cell lines were treated with both compounds simultaneously. The tiophene-derivative selenoester
(2) presented moderate-strong synergism (with CI values ranging between 0.20–0.78) in all tested
drugs except with Cis (CI: 0.96), which suggests that the presence of the sulfur-containing heterocyclic
hydrocarbon moiety in the structure of the tested compounds has a pivotal influence on the efficacy.
Interestingly, compound 2 did not exhibit potent cytotoxic or efflux pump modulatory properties
in our previous study, which suggests that their efficacy is associated with other mechanisms [42].
These results support our previous findings, in relation to organosulfur chalcogens from earlier
studies, as those compounds presented with no pronounced anticancer or EPI modulatory activity,
while displaying strong synergistic interactions with most of the tested drugs (unpublished results).
Interestingly, there were cases, when the reference chalcogen compounds presented synergism with
Molecules 2019, 24, 336 9 of 15
the anticancer drugs (Dox: 13; Top: 12–14; Vin: 14–15; 5-FU: 12–14) in the 25–100 µM concentration
range. However, the cyclic selenoanhydride (1) and phthalic anhydride (12) generally showed similar
interaction profiles, irrespective of the nature of the chalcogen atom included in the molecule (O vs.
Se), as relevant differences were only observed in the case of Top (slight antagonism vs. synergism).
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These observed activities open a new promising approach to fight multidrug resistance in cancer.
Nevertheless, we need to consider that this is a limited preliminary experiment that would require
further studies in more complex models once that the safety of the compounds is established in parallel
studies currently ongoing. While the underlying mechanisms are not yet elucidated, the potency of the
tested selenocompounds as adjuvants may be attributable to their activities are effective modulators
Molecules 2019, 24, 336 10 of 15
of apoptosis and ATP-dependent efflux pumps [42,49]. These pumps, owing to their wide substrate
specificity, can extrude a variety of chemotherapeutic drugs, thus preventing them from reaching
their cellular targets at effective concentrations [21,50–52]. Considering this, it is not surprising that
favorable interactions were observed in relation to Vin, Dox and Top, all being major substrates of these
multidrug efflux pumps (specifically ABCB1 in our model system) [53,54]. However, compounds 1 and
the methyl-ketone selenoesters 9–11 (the most potent EPI inhibitors in previous studies) did not show
superior efficacy in the combination assays (with CI values ranging between 0.41–2.81), thus it would
be safe to assume that other mechanisms should play a role in their pharmacological interactions [43].
This is highlighted by the fact that interactions between the selenocompounds and verapamil (which
exerts cytotoxic as well as pump inhibitor activity in the tested concentration) were negative for
13 out of 15 compounds. Nonetheless, it has been described that some chemotherapeutic drugs
(with the most extensive literature on anthracyclines, vinca alkaloids and camptothecin-analogues
in this respect) exert their antitumor activities not only by binding to specific molecular targets (i.e.,
topoisomerase-I/II enzyme, tubulin-microtubule system), but through a non-specific modulation of
ROS, affecting various cellular components [34,55–57]. Therefore, it is feasible that the cumulative
activity of these ROS-modulating effects might play a role in the interaction profile of the Se-compounds
with the chemotherapeutics, potentiating their anticancer activity against drug resistant lymphoma
cells [58].
3. Materials and Methods
3.1. Chemistry
The synthesis and characterization of the cyclic selenoanhydride (1) and the ten selenoesters
investigated in our study (2–11) was previously described elsewhere [41]. To get the amount of
compound needed for assays, the derivatives were re-synthesized. The 11 compounds were pure and
chemically stable on air, according to the spectroscopic (IR, 1H- and 13C-NMR, MS) and the elemental
analysis performed to confirm the structures of the different derivatives as reported in [41]. 1H and
13C-NMR of representative compounds shown in Supplementary Material (Figures S2–S9). The four
chalcogen compounds (12–15; 12-phthalic anhydride; the oxygen isoster of compound 1, 13-potassium
cyanate, 14-ammonium thiocyanate, 15-potassium selenocyanate) used as references were purchased
(Sigma-Aldrich, St Louis, MO, USA) [43]. Compounds were solved in DMSO to obtain stock solutions.
Afterwards, working solutions were prepared by dilution in water, with the concentration of DMSO
below 1% in all the experiments.
Other chemicals used in the study as reagents were: doxorubicin-hydrochloride (Wako
Pure Chem. Ind., Osaka, Japan), cisplatin (TEVA, Petah Tikva, Israel), 5-fluorouracil (Accord,
North Harrow, UK) topotecan (GlaxoSmithKline, Brentford, London), vincristine (Richter, Budapest,
Hungary), cyclophosphamide (Baxter, Deerfield, IL, USA) verapamil (EGIS, Budapest, Hungary),
methotrexate (Ebewe Pharmaceutical Company, Unterach, Austria), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; Sigma-Aldrich, St Louis, MO, USA), sodium dodecyl sulfate
(SDS; Sigma) and dimethyl-sulfoxide (DMSO; Sigma-Aldrich, St Louis, MO, USA). All solutions were
prepared on the day of assay.
3.2. Cell Lines
L5178Y mouse T-cell lymphoma cells (PAR) (ECACC Cat. No. 87111908, obtained from FDA,
Silver Spring, MD, USA) were transfected with pHa MDR1/A retrovirus, as previously described
by Cornwell et al. [59]. The ABCB1-expressing cell line L5178Y (MDR) was selected by culturing the
infected cells with colchicine. The cells were cultured in McCoy’s 5A medium (Sigma-Aldrich, St Louis,
MO, USA) supplemented with 10% heat-inactivated horse serum (Sigma-Aldrich, St Louis, MO, USA),
200 mM L glutamine (Sigma-Aldrich, St Louis, MO, USA), nystatin and a penicillin-streptomycin
(Sigma-Aldrich, St Louis, MO, USA) mixture in concentrations of 100 IU/L and 10 mg/L, respectively.
Molecules 2019, 24, 336 11 of 15
3.3. Checkerboard Combination Assay
A checkerboard microplate method was applied to study the effect of drug interactions between
the selenocompounds (1–11), chalcogen compounds (12–15) and the reference chemotherapeutic
drugs as well as verapamil [60]. The agents were chosen to include several compounds with
diverse mechanisms of action, while verapamil was included because this compound was used as a
positive control in our previous experiments regarding the efflux pump inhibitory properties of these
compounds [42–44]. The assay was carried out using multidrug-resistant (MDR) mouse T-lymphoma
cells overexpressing the ABCB1 transporter. The final concentration of the chemotherapeutic agents
used in the combination experiment was chosen in accordance with their cytotoxicity on parental and
multidrug-resistant mouse T-lymphoma cells, while the final concentrations of the selenocompounds
used were based on our previous study (for the concentrations of the stock solutions used and the final
concentrations, see the Supplementary material) [42]. The dilutions of the chemotherapeutic drugs
(or verapamil) were made in a horizontal direction in 100 µL, and the dilutions of the selenocompounds
vertically in the microtiter plate in 50 µL volume (see Figure S1. in Supplementary material). The cells
were re-suspended in culture medium and distributed into each well in 50 µL containing 6 × 103 cells
each. The plates were incubated for 72 h at 37 ◦C in 5% CO2 atmosphere. The cell growth rate was
determined after MTT staining. At the end of the incubation period, 20 µL of MTT (thiazolyl blue
tetrazolium bromide, Sigma) solution (from a stock solution of 5 mg/mL) were added to each well.
After incubation at 37 ◦C for 4 h, 100 µL of SDS (Sigma-Aldrich, St. Louis, MO, USA) solution (10%
in 0.01 M HCl; Merck, Darmstadt, Germany) were added to each well and the plates were further
incubated at 37 ◦C overnight. Optical density (OD) was measured at 540/630 nm with Multiscan EX
ELISA reader (Thermo Labsystems, Cheshire, WA, USA) as described elsewhere [60]. Combination
index (CI) values at 50% of the growth inhibition dose (ED50), were determined using CompuSyn
software (ComboSyn, Inc., Paramus, NJ, USA) to plot four to five data points to each ratio [47,61].
CI values were calculated by means of the median-effect equation, according to the Chou-Talalay
method, where CI < 1, CI = 1, and CI > 1 represent synergism, additive effect (or no interaction),
and antagonism, respectively (see Supplementary material) [47,48]. Results are graphically shown in
Figures 2–6 in the previous section (2. Results and Discussion). Detailed results, with the corresponding
standard deviations, are given in Supplementary Material (Tables S3–S10).
4. Conclusions
Herein we have evaluated the capacity of a series of selenocompounds to interact with seven
different chemotherapy drugs (topotecan, doxorubicin, vincristine, cisplatin, cyclophosphamide,
methotrexate and 5-fluorouracil) and the efflux pump inhibitor verapamil, using a checkerboard
microplate method and a MDR mouse T-lymphoma cell line. The results indicated that the
selenocompounds showed a marked capacity to interact with the anticancer drugs tested. Vincristine
was the chemotherapy drug that showed different grades of synergistic interactions with the highest
number of selenocompounds (10), followed by doxorubicin (7 Se-compounds), cyclophosphamide and
methotrexate (6 Se-compounds), topotecan and 5-fluorouracil (5 Se-compounds); whereas interactions
with cisplatin and verapamil were mostly antagonistic. These observations suggest that the tested
Se-compounds can interact with the formation of microtubules and with the action of the cellular
topoisomerase enzymes.
On the other hand, the interaction of Se-compounds that were proven to be active as efflux
pump inhibitors in previous studies was antagonistic with the efflux pump inhibitor verapamil,
which suggests a possible competition among the two classes of efflux inhibitors at the time of their
interaction with their target, the ABCB1 protein. Regarding how the functional groups present in
the Se-compounds affect to the interaction, the symmetrical compounds 2–5, which contain two
selenium atoms, interacted in a synergistic manner with the highest number of chemotherapy drugs,
the thiophene-containing Se-compound 2 was the most efficient in this regard, as it showed synergistic
interactions with all tested drugs except cisplatin. In terms of concentration, the selenoesters 9–11
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(those which contain a ketone in the alkyl chain bound to the selenoester) were able to interact with
topotecan (9–11), vincristine (9–11), doxorubicin (9 and 10) and cyclophosphamide (9) at concentrations
as low as 1.25 µM or 2.5 µM.
Based on our results, these selenocompounds are a promising new class of potential adjuvants of
chemotherapy drugs, that can be used as a novel approach to fight the increasing and troublesome
multidrug resistance in cancer. Although this is an initial work and further research needs to be carried
out for the more-in-depth exploration of the potential applications of these compounds and of their
derivatives that enable the optimization of their desired activities.
Supplementary Materials: The following materials are available online, Tables S1 and S2: Chemotherapeutic
agents and selenocompounds tested; Tables S3–S10: Interactions between selenocompounds and each different
chemotherapeutic drug evaluated; Figure S1: Arrangement of 96-well microtiter plates for checkerboard
combination assay; Figures S2–S5: 1H-NMR spectra of selected compounds; Figures S6–S9: 13C-NMR spectra of
selected compounds.
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